Psychooncology:前列腺癌术后的社会约束和心理健康研究

2017-10-19 AlexYang MedSci原创

之前的研究表明了社会约束(情绪表达障碍)也许是影响心理健康的一个风险因子。最近,有研究人员进行了旨在调查前列腺癌相关的前列腺术后社会约束和心理健康之间的关系的研究。研究包括了3478名包括同伴病人,这些病人参与了机器人腹腔镜前列腺切除术开放(LAPPRO)试验,并且该试验为一个前列腺癌的机器人协助的腹腔镜检查和耻骨后前列腺癌根治术的前瞻性、多中心比较研究,研究人员在该研究中利用了log-binom

之前的研究表明了社会约束(情绪表达障碍)也许是影响心理健康的一个风险因子。最近,有研究人员进行了旨在调查前列腺癌相关的前列腺术后社会约束和心理健康之间的关系的研究。研究包括了3478名包括同伴病人,这些病人参与了机器人腹腔镜前列腺切除术开放(LAPPRO)试验,并且该试验为一个前列腺癌的机器人协助的腹腔镜检查和耻骨后前列腺癌根治术的前瞻性、多中心比较研究,研究人员在该研究中利用了log-binomial回归分析来调查术后3个月前列腺癌相关的社会约束与第12个月和24个月心理健康之间的联系。

研究发现,在第12个月和24个月,分别有1086名男性和1093名男性报道心理健康程度低。同伴的前列腺癌相关的社会约束能够预测第12个月的低心理健康程度(adjusted RR: 1.4; 95% CI, 1.1-1.9),其他人的社会约束也能够进行第12个月的低心理健康程度预测(adjusted RR: 1.9; 95% CI, 1.1-3.5)。另外,侵入性想法能够调控社会约束和心理健康之间的关系。

最后,研究人员指出,社会环境的消极响应,尤其是同伴的关于前列腺癌经历的讨论能够在根治性前列腺癌切除术后影响病人心理健康2年。研究强调了帮助病人动用他们的社交网络心理资源的重要性,尤其是那些缺乏高质量的心理社会支持的病人。

原始出处:

Kollberg KS, Thorsteinsdottir T, Wilderäng U et al. Social constraints and psychological well-being after prostate cancer: a follow-up at 12 and 24 months after surgery. Psychooncology. 12 Oct 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674425, encodeId=0d2a16e44256d, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Jul 22 22:19:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865152, encodeId=b54418651525c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 02 20:19:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506598, encodeId=460d15065981b, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616743, encodeId=e0e41616e4392, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254550, encodeId=cac7254550e5, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Oct 20 09:28:33 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674425, encodeId=0d2a16e44256d, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Jul 22 22:19:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865152, encodeId=b54418651525c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 02 20:19:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506598, encodeId=460d15065981b, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616743, encodeId=e0e41616e4392, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254550, encodeId=cac7254550e5, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Oct 20 09:28:33 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-12-02 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674425, encodeId=0d2a16e44256d, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Jul 22 22:19:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865152, encodeId=b54418651525c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 02 20:19:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506598, encodeId=460d15065981b, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616743, encodeId=e0e41616e4392, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254550, encodeId=cac7254550e5, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Oct 20 09:28:33 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674425, encodeId=0d2a16e44256d, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Jul 22 22:19:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865152, encodeId=b54418651525c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 02 20:19:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506598, encodeId=460d15065981b, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616743, encodeId=e0e41616e4392, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254550, encodeId=cac7254550e5, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Oct 20 09:28:33 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674425, encodeId=0d2a16e44256d, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Jul 22 22:19:00 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865152, encodeId=b54418651525c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Dec 02 20:19:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506598, encodeId=460d15065981b, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616743, encodeId=e0e41616e4392, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Sat Oct 21 13:19:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254550, encodeId=cac7254550e5, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Oct 20 09:28:33 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 139****5926

    好好文章学习了

    0

相关资讯

Eur Urol:淋巴结阳性前列腺癌患者根治性前列腺切除术后生存结局:不同术后管理策略的比较分析。

在本研究中,研究者评估了三种不同的管理策略与根治性前列腺切除术后发生淋巴结转移的患者的生存关系。

J Urol: 前列腺癌发生率和前列腺特异抗原筛选流行度分析

在美国国家预防服务工作组(USPSTF)推荐的预防常规PSA工作之后,前列腺特异性抗原(PSA)筛选和前列腺癌发生率的减少是否与社会经济组织和美国人口普查区域之间是相似的这个问题仍旧不清楚。最近,有研究人员通过调查年龄、种族、疾病阶段、美国地区和区域社会经济状态分析了前列腺癌发生率和PSA筛选流行度。研究人员调查了年度百分比变化速率,并计算了边际概率和95%置信区间(CI)来评估PSA筛选流行度变

Sci Rep:胚胎特异性蛋白1(PLAC1)是抗体-药物结合治疗前列腺癌免疫疗法的潜在靶标

之前,有研究人员指出他们的发现强烈的支持了PLAC1可作为前列腺癌(PCa)免疫疗法靶标的想法。最近,他们制作并评估了基于抗胚胎特异性蛋白1(PLAC1)的抗体药物结合体(ADC)对前列腺癌的靶标免疫治疗。研究发现,前列腺癌细胞表达出了可观的PLAC1水平。PLAC1克隆抗体2H12C12在前列腺细胞中表现出了与重组PLAC1高度的反映力和对PLAC1的选择性识别,但是在阴性对照LS180细胞中并

Prostate:白花丹素可以提高治疗前列腺癌的雄激素疗法阻断效果

白花丹素是治疗前列腺癌的候选药物。之前的研究表明了白花丹素也许可以提高雄激素阻断疗法(ADT)的治疗效果。最近,有研究人员评估了将白花丹素和ADT结合在前列腺癌小鼠模型中进行试验,从而支持白花丹素的临床应用。研究人员利用新的芝麻油配方进行白花丹素口腔服用,并在小鼠中进行了标准的毒性研究。对肿瘤生长研究,研究人员将小鼠前列腺癌细胞团嫁接到前列腺组织上来形成肿瘤。小鼠被分成不同处理的小组,肿瘤大小通过

Eur Urol:比较醋酸阿比特龙和多西他赛联合雄激素剥夺治疗在高风险和转移性未经激素治疗的前列腺癌中的作用:系统评价与荟萃分析。

最近,随机临床试验已经验证了在使用激素剥夺疗法(ADT,使用波尼松/泼尼松龙)治疗未经激素治疗的晚期前列腺癌(PCa)时联合多西他赛或阿比特龙的益处。

临床试验希望为前列腺癌提供毒性较小的治疗

在过去的十年中,免疫疗法已经成为肿瘤学领域最有前途和创新的领域之一。免疫疗法的目标是利用患者自身的免疫系统对抗癌症。2010年,美国食品和药物管理局(FDA)批准了第一种癌症治疗疫苗sipuleucel - T(品牌名称来源),用于治疗前列腺癌。Roswell Park癌症研究所泌尿生殖医学临床主任Gurkamal Chatta博士说:"从那时起,已经有其他免疫治疗前列腺癌的临床试验,但是我们还没